Maryland Psychiatric Research Center
Catonsville, Maryland 21716
3 studies enrolling now · 36 studies all time
What they study most
Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Cannabis Use, Celiac Disease, Chronic Schizophrenia, Cocaine Abuse, Cocaine Use, Cognitive Impairment, Gluten Sensitivity, Hyperprolactinemia, Schizoaffective Disorder, Schizophrenia
Studies at this site
- White Matter Plasticity in Schizophrenia — Recruiting now
- TMS for Inhibition Enhancement in Schizophrenia — Recruiting now
- Diclofenac Dose Response Study — Recruiting now
- Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia — Stopped early
- Cigarette Smoking in Smokers With and Without Schizophrenia — Completed
- Tryptophan MRI in People With Schizophrenia and Healthy Controls — Completed
- Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN) — Completed
- Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study — Withdrawn before enrolling
- An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms — Completed
- Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients — Completed
- Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia — Completed
- Biological Evaluation of Dietary Supplement Liposomal Glutathione — Completed
- Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis — Withdrawn before enrolling
- L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder — Withdrawn before enrolling
- Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine — Completed
- Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia — Completed
- Gluten Free Diet in People With Schizophrenia: A Pilot Study — Completed
- Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use — Completed
- Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive — Completed
- Neuroendocrine and Immune Response to Stress in Schizophrenia — Completed
- Intracellular Tight Junction Permeability in Schizophrenia: Focus on Zonulin — Completed
- Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia — Completed
- Tobacco Craving and Triggers in Persons With Schizophrenia — Completed
- Effects of Oxytocin Nasal Spray on Social Affiliation — Completed
- Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients — Completed
- Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia — Completed
- Screening Protocol for Research Participants — Completed
- Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia — Withdrawn before enrolling
- Schizophrenia and the Gut Microbiome — Completed
- Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia — Completed
- New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia — Completed
- A Comparison of Bupropion SR and Placebo for Smoking Cessation — Completed
- A Multicenter Study of NAP (AL-108) in Schizophrenia — Completed
- Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia — Withdrawn before enrolling
- Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults — Completed
- Treatment Study for Cognitive Deficits in Schizophrenia — Completed